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Imaging of Cerebral Amyloid 
Angiopathy with Bivalent  
99mTc-Hydroxamamide Complexes
Shimpei Iikuni1, Masahiro Ono1, Hiroyuki Watanabe1, Kenji Matsumura1, Masashi Yoshimura1, 
Hiroyuki Kimura1, Hatsue Ishibashi-Ueda2, Yoko Okamoto2, Masafumi Ihara3 & Hideo Saji1
Cerebral amyloid angiopathy (CAA), characterized by the deposition of amyloid aggregates in the 
walls of cerebral vasculature, is a major factor in intracerebral hemorrhage and vascular cognitive 
impairment and is also associated closely with Alzheimer’s disease (AD). We previously reported 99mTc-
hydroxamamide (99mTc-Ham) complexes with a bivalent amyloid ligand showing high binding affinity for 
β-amyloid peptide (Aβ(1–42)) aggregates present frequently in the form in AD. In this article, we applied 
them to CAA-specific imaging probes, and evaluated their utility for CAA-specific imaging.  
In vitro inhibition assay using Aβ(1–40) aggregates deposited mainly in CAA and a brain uptake study 
were performed for 99mTc-Ham complexes, and all 99mTc-Ham complexes with an amyloid ligand showed 
binding affinity for Aβ(1–40) aggregates and very low brain uptake. In vitro autoradiography of human 
CAA brain sections and ex vivo autoradiography of Tg2576 mice were carried out for bivalent 99mTc-Ham 
complexes ([99mTc]SB2A and [99mTc]BT2B), and they displayed excellent labeling of Aβ depositions in 
human CAA brain sections and high affinity and selectivity to CAA in transgenic mice. These results may 
offer new possibilities for the development of clinically useful CAA-specific imaging probes based on the 
99mTc-Ham complex.
Cerebral amyloid angiopathy (CAA) is a sporadic or familial disorder characterized by the deposition of amyloid 
aggregates, mainly β -amyloid peptide (Aβ ), in the walls of arteries and less often capillaries of the central nervous 
system, and belongs to the amyloidosis group1,2. CAA is present in 10–40% of the elderly3. In particular, at least a 
mild degree of CAA can be detected in up to 80% of patients with Alzheimer’s disease (AD)3, while severe CAA 
is present in approximately 25% of AD brains4.
CAA is a major cause of intracerebral hemorrhage (ICH) and vascular cognitive impairment5–7, and is 
also associated with small vessel diseases such as white matter hyperintensity and cerebral microbleeds6,8,9. 
CAA-associated ICH (CAA-ICH) comprises 5–20% of all spontaneous ICH in the elderly1,3. CAA-ICH is fre-
quently a fatal condition and often recurs because of the multiple and widespread depositions of aggregated amy-
loid peptides in CAA brains1,7. Moreover, it was demonstrated that vascular diseases in the brain led to a decline 
of cognitive performance in the earliest stages of AD10,11.
Aβ (1–40) with a length of 40 amino acids is more soluble than longer Aβ (1–42) and is the main form in amy-
loid deposited in walls of blood vessels in CAA brains, while Aβ (1–42) is present more frequently in the form of 
senile plaque (SP) within the brain parenchyma in AD brains1,2. In patients with amyloidoses including CAA and 
AD, amyloid aggregates probably appear prior to onset of disease symptoms12,13; therefore, their detection in vivo 
may lead to an early diagnosis of the corresponding amyloidoses. Additionally, monitoring these amyloid aggre-
gates in vivo may provide important information on the development of new medical techniques.
Brain biopsy is the gold standard for the diagnosis of CAA7; however, it is a highly invasive method. Although 
computed tomography (CT) and magnetic resonance imaging (MRI) are noninvasive and useful modalities for 
the diagnosis of CAA-ICH14,15, they detect intracerebral bleeding but not the deposition of amyloid aggregates; 
therefore, these indirect diagnostic techniques are unlikely to facilitate disease-specific diagnoses limited by the 
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use of ICH as a surrogate marker for CAA. Accordingly, the development of a noninvasive technique to diagnose 
CAA-associated diseases specifically by the detection of amyloid using a probe is strongly needed.
Positron emission tomography (PET) and single photon emission computed tomography (SPECT) have 
generally been utilized as major in vivo imaging techniques to carry out the noninvasive diagnosis of amyloi-
doses. PET/SPECT can provide the information on localization of amyloid aggregates, while CT and MRI ren-
der the anatomical information. To date, many attempts to image Aβ aggregates constituting SP in AD brains 
using PET and SPECT tracers have been made. Several clinical studies using [11C]PIB, a neutral thioflavin-T 
analogue, have proved this utility for AD diagnosis16–19. More recently, [18F]florbetapir (Amyvid)17,20,21, [18F]
flutemetamol (Vizamyl)16,22,23, and [18F]florbetaben (Neuraceq)24,25 have been approved by the US Food and Drug 
Administration for clinical AD diagnosis.
Similarly to SP in AD brains, there are several reports regarding the detection of cerebrovascular amyloid dep-
ositions using [11C]PIB26–28. However, since [11C]PIB is designed to penetrate the blood-brain barrier (BBB), it is 
considered to bind to not only vascular amyloid aggregates but also parenchymal amyloid aggregates, indicating 
that it detects amyloid depositions in the whole brain; therefore, [11C]PIB cannot help detecting SP as background 
signal in case of the diagnosis of CAA. Several efforts toward the development of imaging probes targeting Aβ 
deposition in CAA have been made. These probes, designed as fluorescent dye29, MRI contrast30–32, or PET/
SPECT imaging31–34 agents, showed a potential use for CAA; however, in vivo specificity for Aβ aggregates in 
CAA was not demonstrated. Further research into the development of imaging probes for selective binding to Aβ 
deposited in the walls of the cerebral vasculature and to differentiate CAA from AD is desired.
To detect CAA but not SP, low brain uptake of an imaging probe targeting Aβ aggregates may be favora-
ble33,34. We previously reported a series of 99mTc-hydroxamamide (99mTc-Ham) complexes with a multivalent 
amyloid ligand35, and utilized stilbene (SB) and benzothiazole (BT) as ligands for amyloid aggregates. These 
compounds are believed to hardly cross the BBB in vivo, and their high binding affinity for Aβ aggregates is feasi-
ble for imaging CAA. However, in that report, the binding affinity of 99mTc-Ham complexes was evaluated using 
Aβ (1–42) aggregates present mainly in SP and less often CAA. It is generally accepted that compounds with high 
binding affinity for Aβ (1–42) aggregates except for antibodies can bind to other amyloid aggregates such as tau 
and α -synuclein36–38. Therefore, 99mTc-Ham complexes are considered to bind to Aβ (1–40) aggregates, the pre-
dominant amyloid found in CAA, similarly to Aβ (1–42) aggregates.
In the present study, we evaluated the binding affinity for Aβ (1–40) aggregates deposited mainly in CAA of 
99mTc-Ham complexes with a monovalent or bivalent amyloid ligand ([99mTc]SB1, [99mTc]SB2, [99mTc]BT1, and 
[99mTc]BT2) (Fig. 1), and their utility for the in vivo specific detection of vascular amyloid aggregates but not 
parenchymal amyloid aggregates.
Figure 1. Proposed structure of the 99mTc-Ham complexes. 
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Results
Synthesis and 99mTc labeling. The 99mTc labeling reaction was performed by the complexation reaction 
using the Ham precursor, 99mTc-pertechnetate, and tin (II) tartrate hydrate as a reducing agent35. The 99mTc com-
plexation reaction with Ham derivatives provided two isomers of 99mTc-Ham complexes, as described in previous 
reports35,39. We defined the specific isomers with shorter retention times on reversed-phase high-performance 
liquid chromatography (RP-HPLC) as A-form ([99mTc]SB1A, [99mTc]SB2A, [99mTc]BT1A, and [99mTc]BT2A), and 
the others as B-form ([99mTc]SB1B, [99mTc]SB2B, [99mTc]BT1B, and [99mTc]BT2B).
99mTc-Ham complexes showed high binding affinity for Aβ(1–40) aggregates in solution. To 
evaluate binding affinity for Aβ (1–40) aggregates of 99mTc-Ham complexes, we performed an inhibition binding 
assay with PIB as a competitive ligand. A fixed concentration of Aβ (1–40) aggregates and the 99mTc-Ham complex 
were incubated with increasing concentrations of nonradioactive PIB. PIB showed IC50 values of 0.38, 0.45, 4.59, 
3.37, 0.24, 0.99, 1.58, and 4.96 μ M in the presence of [99mTc]SB1A, [99mTc]SB1B, [99mTc]SB2A, [99mTc]SB2B, [99mTc]
BT1A, [99mTc]BT1B, [99mTc]BT2A, and [99mTc]BT2B, respectively (Table 1).
Assessment of BBB permeability. To evaluate brain uptake of 99mTc-Ham complexes, biodistribution 
experiments of 99mTc-Ham complexes were performed in normal mice. We selected 18F-florbetapir as a control 
and compared the results of 99mTc-Ham complexes with that of 18F-florbetapir (Fig. 2). The brain uptake of [99mTc]
SB1A, [99mTc]SB2A, [99mTc]BT1B, and [99mTc]BT2B at 2 min postinjection was 0.37, 0.28, 0.36, and 0.37% injected 
dose (ID)/g, respectively. The radioactivity in the brains remained low until 60 min postinjection. The results of 
the biodistribution study are shown in Table S1 in Supplementary information.
99mTc-Ham complexes including bivalent amyloid ligand displayed excellent labeling of Aβ dep-
ositions in human CAA brain sections. The binding of [99mTc]SB2A and [99mTc]BT2B to Aβ depositions 
Compound
IC50 of PIB (μM)*
Aβ(1–40) Aβ(1–42)†
[99mTc]SB1A 0.38 ± 0.06 0.72 ± 0.10
[99mTc]SB1B 0.45 ± 0.11 0.38 ± 0.08
[99mTc]SB2A 4.59 ± 0.77 16.40 ± 2.47
[99mTc]SB2B 3.37 ± 0.61 2.55 ± 0.45
[99mTc]BT1A 0.24 ± 0.06 0.26 ± 0.02
[99mTc]BT1B 0.99 ± 0.17 0.47 ± 0.05
[99mTc]BT2A 1.58 ± 0.27 2.80 ± 0.32
[99mTc]BT2B 4.96 ± 0.90 5.78 ± 0.53
Table 1.  Half-maximal inhibitory concentration (IC50, μM) for the binding of PIB to Aβ aggregates 
determined using 99mTc-Ham complexes as ligands. *Values are the mean ± standard error of the mean of 6–15 
independent experiments. †Data from our previous article (ref. 35).
Figure 2. Comparison of radioactivity of extracted brain tissues after intravenous injection of 99mTc-Ham 
complexes and [18F]florbetapir in normal mice. Values are the mean ± standard deviation of 5 animals. *Data 
from our previous article (ref. 45).
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in brain sections from a CAA patient was evaluated by in vitro autoradiography. In CAA brain sections, [99mTc]
SB2A intensively labeled Aβ depositions (Fig. 3A), while almost no accumulation of radioactivity was observed 
in the control brain sections (Fig. 3D). Furthermore, the labeling pattern was consistent with the immunohisto-
chemical staining pattern observed in the same brain sections with anti-Aβ (1–40) antibody (Fig. 3B). In addition, 
the labeling of Aβ depositions with [99mTc]SB2A was blocked to a large extent with an excess of nonradioactive 
PIB (Fig. 3C). In vitro autoradiography with [99mTc]BT2B showed a similar result to that of [99mTc]SB2A (Fig. S1 
in Supplementary information). Moreover, [99mTc]SB2A and [99mTc]BT2B also intensively labeled Aβ depositions 
in brain sections from another patient with CAA (Fig. S2 in Supplementary information).
99mTc-Ham complexes including bivalent amyloid ligand exhibited high affinity and selectivity 
to CAA in transgenic mice. To confirm the affinity of [99mTc]SB2A and [99mTc]BT2B for Aβ aggregates in a 
mouse brain, ex vivo autoradiography was performed using Tg2576 and wild-type mice (Fig. 4). The brains were 
removed at 30 min postinjection for autoradiography. Ex vivo autoradiograms with [99mTc]SB2A displayed inten-
sive labeling of Aβ depositions in the transgenic mice (Fig. 4A,B) but not the age-matched controls (Fig. 4C). The 
labeling pattern on autoradiograms was partially consistent with the staining pattern observed in the same brain 
sections from Tg2576 mice with thioflavin-S, a dye commonly used to stain Aβ depositions (Fig. 4D,E), while 
there was no marked staining in the wild-type mouse brain sections (Fig. 4F). However, some Aβ depositions 
were not labeled with [99mTc]SB2A in Tg2576 mouse brain sections. To confirm whether [99mTc]SB2A labeled Aβ 
aggregates deposited within vascular or parenchyma, the same sections were immunostained with anti-CD31 
antibody, a marker for endothelial cells (Fig. 4G–I)40,41. The accumulation of radioactivity on autoradiograms 
was observed only at Aβ depositions labeled with both thioflavin-S and anti-CD31 antibody (Fig. 4B,E and H, 
red arrows), while no radioactive spots were observed at Aβ depositions labeled with thioflavin-S, not anti-CD31 
antibody (Fig. 4E, white arrowheads). Furthermore, ex vivo autoradiography with [99mTc]BT2B showed a similar 
result to that of [99mTc]SB2A (Fig. S3 in Supplementary information).
Discussion
We previously reported 99mTc-Ham complexes with a bivalent amyloid ligand showing high binding affinity for 
Aβ (1–42) aggregates35. In the present study, we evaluated their utility as CAA-specific imaging probes. Recently, 
several new 99mTc-labeled CAA imaging agents were reported42–44. In spite of the fact that they were synthesized 
under heating and acidic conditions, 99mTc-Ham complexes can be prepared under mild conditions (non-heating 
and neutral), indicating that 99mTc-Ham complexes may be superior to the other CAA-imaging probes reported 
previously. In vitro binding study using Aβ (1–40) aggregates, a major form of amyloid in CAA, exhibited that 
the amyloid ligand dimers ([99mTc]SB2 and [99mTc]BT2) bound to Aβ (1–40) aggregates more strongly than their 
monomers ([99mTc]SB1 and [99mTc]BT1), and A-form of 99mTc-Ham complexes with BT derivatives showed 
lower binding affinity than B-form, as demonstrated in our previous report using Aβ (1–42) aggregates (Table 1). 
However, specific isomers of 99mTc-Ham complexes with SB derivatives displayed similar binding affinity for 
Aβ (1–40) aggregates to those of the other isomers, while significant differences between IC50 values with two iso-
mers of SB derivatives were shown in the inhibition assay using Aβ (1–42) aggregates35. All 99mTc-Ham complexes 
showed blocked binding to amyloid aggregates with a very high concentration (μ M order) of PIB, although the 
Aβ imaging probes reported previously have a binding affinity equal to or lower than that of PIB, suggesting that 
they have a much higher binding affinity than any other tracers targeting Aβ including CAA-specific imaging 
Figure 3. In vitro autoradiogram of a brain section from a patient with CAA (female, 67 years old) labeled with 
[99mTc]SB2A (A). The same brain section was immunostained with an antibody against Aβ (1 –40) (B). Blocking 
study with nonradioactive PIB was also performed using the adjacent brain section (C). In vitro autoradiogram 
of a brain section from a healthy control (male, 73 years old) labeled with [99mTc]SB2A (D).
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probes44. Among eight 99mTc-Ham complexes, both [99mTc]SB2A and [99mTc]BT2B showed high binding affinity 
for Aβ (1–40) aggregates (4.59 and 4.96 μ M, respectively), which was higher than those of any other 99mTc-Ham 
complexes.
According to the result of the inhibition assay using Aβ (1–40) and Aβ (1–42) aggregates, brain uptake studies 
were performed for only specific isomers with the higher binding affinity for Aβ aggregates (A-form of SB deriv-
atives and B-form of BT derivatives). [99mTc]SB1A, [99mTc]SB2A, [99mTc]BT1B, and [99mTc]BT2B displayed much 
lower initial brain uptake than [18F]florbetapir under similar experimental conditions (4.90%ID/g at 2 min post-
injection) (Fig. 2)45, while [18F]florbetapir has proved its utility for imaging Aβ plaques in the brain. In addition, 
99mTc-Ham complexes also showed a lower initial brain entry than even other CAA imaging probes reported 
previously (0.61–1.21%ID/g at that time)44. These results suggest that 99mTc-Ham complexes could hardly cross 
the BBB. Therefore, they may be incapable of binding to Aβ aggregates deposited within the brain parenchyma. 
According to the results of binding affinity for Aβ (1–40) and Aβ (1–42) aggregates in vitro and brain uptake in 
normal mice ex vivo, further studies were conducted using [99mTc]SB2A and [99mTc]BT2B with high binding affin-
ity for Aβ aggregates and very low brain uptake.
In vitro autoradiography of human CAA brain sections with [99mTc]SB2A showed intensive labeling of Aβ 
depositions (Fig. 3A), confirmed by immunostaining of the same brain sections with anti-Aβ (1–40) antibody 
(Fig. 3B). Many 99mTc-labeled Aβ imaging probes with preferable binding affinity have exhibited no marked labe-
ling of Aβ depositions in human brain sections; however, Jia et al. recently reported a 99mTc-labeled tracer show-
ing positive autoradiography results for brain sections from AD patients44. As well as those results, 99mTc-Ham 
complexes showed excellent labeling of Aβ depositions in human brain sections. Additionally, a blocking study 
with nonradioactive PIB confirmed the specific binding of [99mTc]SB2A to Aβ depositions in CAA brain sections 
(Fig. 3C). In vitro autoradiography with [99mTc]BT2B showed specific binding to Aβ depositions in CAA brain 
sections as well as [99mTc]SB2A (Fig. S1 in Supplementary information). In addition, two bivalent 99mTc-Ham 
complexes, [99mTc]SB2A and [99mTc]BT2B, also showed intensive labeling of Aβ depositions in brain sections from 
another patient with CAA (Fig. S2 in Supplementary information).
Ex vivo autoradiography with [99mTc]SB2A displayed specific binding to Aβ aggregates in the living Tg2576 
mouse brain (Fig. 4A,B) but not wild-type mouse brain (Fig. 4C). Since Tg2576 mice are known to overproduce 
Aβ aggregates in the brain, they have been commonly used to evaluate the specific binding of Aβ aggregates 
in experiments in vitro and in vivo45,46. The accumulation of radioactivity in Tg2576 mouse brain sections was 
Figure 4. Ex vivo autoradiograms (ARG) from Tg2576 (A) and wild-type (C) mice with [99mTc]SB2A. The 
same sections were stained with thioflavin-S (ThS) (D,F). The same sections were also immunostained with 
an antibody against CD31 (G,I). Panel B,E,H represent magnified image details of panel A,D,G, respectively. 
Red arrows show Aβ depositions labeled with both ThS and anti-CD31 antibody. White arrowheads show Aβ 
depositions labeled with ThS, not anti-CD31 antibody.
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observed only at the presence of both amyloid aggregates (Fig. 4D,E) and endothelial cells (Fig. 4G,H), suggesting 
that [99mTc]SB2A selectively bound to amyloid aggregates deposited along vessels but not within parenchyma. 
In addition, [99mTc]BT2B displayed specific detection of CAA in Tg2576 mice (Fig. S3 in Supplementary infor-
mation). These results are consistent with the biodistribution study showing the low brain entry of 99mTc-Ham 
complexes. These findings in the present study suggest that our bivalent 99mTc-Ham complexes, [99mTc]SB2A and 
[99mTc]BT2B, can specifically detect CAA in vivo. However, these tracers seemed to label areas in the cortex that 
are not apparent in the thioflavin-S staining. Thioflavin-S has much lower affinity (Kd: μ M order) than useful 
Aβ imaging probes reported previously such as PIB, florbetapir (Kd: nM order)19,47. An in vitro inhibition assay 
showed that our 99mTc-labeled compounds blocked binding to Aβ aggregates due to a much higher concentration 
of unlabeled-PIB, suggesting that our compounds have a much higher binding affinity than other Aβ and CAA 
imaging agents reported previously. Accordingly, it is considered that thioflavin-S can detect fewer depositions 
of amyloid than our compounds. In addition, we also carried out ex vivo autoradiography using perfused mouse 
brains, and obtained results showing differences with Tg2576 and wild-type mice (data not shown), suggesting 
that radioactivity was derived from tracers binding to depositions of amyloid, and not from tracers contained in 
the blood. Although the possibility that the BBB is leaky in the brains of AD patients has been suggested in sev-
eral reports48,49, it has remained controversial whether or not the BBB dysfunction depends on the stage of AD. 
Not all studies have indentified an index of BBB disruption in AD brains50–52, but Zipser et al. recently reported 
that dysfunction of the BBB could increase stepwisely with the degree of pathology in AD53, indicating that the 
BBB should be intact in an early stage of preclinical AD. Moreover, CAA imaging probes should be used in the 
preclinical stage of the disease when the BBB functions normally. Therefore, 99mTc-Ham complexes developed in 
the present study, which may be incapable of penetrating the BBB, can serve as CAA-specific imaging probes for 
the early diagnosis of AD.
In addition, we performed an in vivo SPECT/CT study with [99mTc]SB2A using Tg2576 and wild-type mice at 
30 min postinjection (Fig. S4 in Supplementary information). Although ex vivo autoradiography demonstrated 
the specificity of [99mTc]SB2A for CAA, [99mTc]SB2A was not differentially distributed in the brains of Tg2576 and 
wild-type mice in vivo. The radioactivity accumulation was observed mostly in the limbic region of the brain, 
which seemed to be derived from the blood. This inference is supported by the observations that blood vessels 
were rich in this region of the brain confirmed by immunostaining of CD31 (Fig. 4G,I), and a biodistribution 
study which suggested that [99mTc]SB2A has a high retention rate in the blood (5.13%ID/g at 30 min postinjec-
tion, Table S1 in Supplementary information). Although the influence of radioactivity in the cerebral blood could 
be removed by perfusion in ex vivo autoradiography examination, it was inevitable to detect radioactivity in the 
blood as a background signal in the in vivo SPECT study. Furthermore, we carried out an in vivo SPECT imaging 
study at a later time point (120 min postinjection) of [99mTc]SB2A. However, we obtained a similar result to that 
of at 30 min postinjection, suggesting that the radioactivity in the blood still remained at 120 min postinjection 
(Fig. S5 in Supplementary information). Therefore, further acceleration of the clearance of 99mTc-labeled probes 
from the blood pool is essential for the development of in vivo imaging probes targeting CAA. The introduction 
of a hydrophilic substituted group including hydroxyl and carboxyl groups may constitute one of the strategies 
to enhance the clearance of probes from the blood. For instance, the replacement of the dimethylamino group 
in [99mTc]SB2A with a hydroxyl group reduces its lipophilicity, contributing to lower binding to plasma proteins. 
This modification of probes should facilitate the more rapid clearance of [99mTc]SB2A from the blood, leading to a 
lower background signal that can bring about an increase in the specific signal of the probes on binding to CAA.
In the current study, we applied bivalent 99mTc-Ham complexes that we reported previously to imaging probes 
targeting CAA. All 99mTc-Ham complexes including a monovalent or bivalent amyloid ligand showed binding 
affinity for Aβ (1–40) aggregates in vitro and very low brain uptake in normal mice ex vivo. In vitro autoradiog-
raphy showed specific binding of 99mTc-Ham complexes including a bivalent amyloid ligand ([99mTc]SB2A and 
[99mTc]BT2B) with high binding affinity in the inhibition assay to Aβ depositions in brain sections from a CAA 
patient. Additionally, [99mTc]SB2A and [99mTc]BT2B displayed excellent and selective labeling of Aβ depositions in 
vessels but not parenchyma in mouse brains. The results suggest that [99mTc]SB2A and [99mTc]BT2B have potential 
as CAA-specific imaging probes. Although the in vivo SPECT/CT study with [99mTc]SB2A showed no marked dif-
ference in radioactivity accumulation in the brain between Tg2576 and wild-type mice, the findings in the pres-
ent study reveal new possibilities of developing clinically useful CAA imaging probes based on the 99mTc-Ham 
complex. Further optimization to improve the clearance of 99mTc-Ham complexes from the blood is underway.
Methods
General. All reagents were obtained commercially and used without further purification unless otherwise 
indicated. PIB was purchased from ABX (Saxony, Germany). Na99mTcO4 was purchased from Nihon Medi-
Physics Co., Ltd. (Tokyo, Japan) or was obtained from a commercial 99Mo/99mTc generator (Ultra-Techne Kow; 
FUJIFILM RI Pharma Co., Ltd., Tokyo, Japan). RP-HPLC was performed with a Shimadzu system (SHIMADZU, 
Kyoto, Japan, a LC-20AT pump with a SPD-20A UV detector, λ = 254 nm) with a Cosmosil C18 column (Nacalai 
Tesque, Kyoto, Japan, 5C18-AR-II, 4.6 mm × 150 mm) using a mobile phase (10 mM phosphate buffer (pH 7.4)/
acetonitrile: 0 min 3/2 to 30 min 3/7) delivered at a flow rate of 1.0 mL/min.
Animals. Animal experiments were conducted in accordance with our institutional guidelines and were 
approved by the Kyoto University Animal Care Committee. Male ddY mice were purchased from Japan SLC, Inc. 
(Shizuoka, Japan). Female Tg2576 mice and wild-type mice were purchased from Taconic Farms, Inc. (New York, 
USA). Animals were fed standard chow and had free access to water. All efforts were made to minimize suffering.
Human brain tissues. Experiments involving human subjects were performed in accordance with relevant 
guidelines and regulations and were approved by the ethics committee of Kyoto University and National Cerebral 
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and Cardiovascular Center. Informed consent was secured from all subjects in this study. Postmortem brain tis-
sues from autopsy-confirmed cases of CAA (female, 67 years old, and female, 85 years old) and a control (male, 
73 years old) were obtained from the Graduate School of Medicine, Kyoto University, National Cerebral and 
Cardiovascular Center, and BioChain Institute, Inc. (California, USA), respectively.
Synthesis and 99mTc labeling. 99mTc-Ham complexes ([99mTc]SB1, [99mTc]SB2, [99mTc]BT1, and [99mTc]
BT2) were prepared as we reported previously35. In brief, to solutions of 0.2 mg Ham precursors ((Z)-4-((E)-
4-(dimethylamino)styryl)-N’-hydroxybenzimidamide, (Z)-2-(4-(dimethylamino)phenyl)-N’-hydroxybenzo[d]
thiazole-6-carboximidamide, and (Z)-4-(dimethylamino)-N’-hydroxybenzimidamide) in acetate/ethanol (1/4, 
200 μ L) were added 100 μ L Na99mTcO4 solution and 15 μ L tin (II) tartrate hydrate solution [2 mg tin (II) tartrate 
hydrate (7.50 μ mol) dissolved in water (2.5 mL)]. The reaction mixtures were incubated at room temperature 
for 30 min and purified by RP-HPLC. The 99mTc-Ham complexes were analyzed by analytical RP-HPLC on a 
Cosmosil C18 column (5C18-AR-II, 4.6 mm × 150 mm) with a solvent of phosphate buffer (10 mM, pH 7.4)/ace-
tonitrile (0 min 3/2 to 30 min 3/7) as the mobile phase at a flow rate of 1.0 mL/min. The radioactivity of the 
99mTc-labeled compounds was recorded for 30 min.
Competitive inhibition assay using Aβ(1–40) aggregates in solution. A solid form of Aβ (1–40) 
was purchased from the Peptide Institute (Osaka, Japan). Aggregation was carried out by gently dissolving the 
peptide (0.50 mg/mL) in phosphate-buffered saline (PBS) (pH 7.4). The solution was incubated at 37 °C for 42 h 
with gentle and constant shaking. A mixture containing 50 μ L Aβ (1–40) aggregates (final conc., 1.25 μ g/mL), 50 μ 
L 99mTc-Ham complex (final conc., 8.3 kBq/mL), 50 μ L PIB (final conc., 64 pM–125 μ M in 30% EtOH), and 850 μ L 
of 30% EtOH was incubated at room temperature for 3 h. The mixture was filtered through Whatman GF/B filters 
(Whatman, Kent, U.K.) using a Brandel M-24 cell harvester (Brandel, Maryland, USA), and the radioactivity 
of the filters containing the bound 99mTc-Ham complex was measured using a γ counter (Wallac 1470 Wizard; 
PerkinElmer, Massachusetts, USA). Values for the half-maximal inhibitory concentration (IC50) were determined 
from displacement curves using GraphPad Prism 5.0 (GraphPad Software, Inc., California, USA).
Ex vivo biodistribution in normal mice. A saline solution (100 μ L) of 99mTc-Ham complexes (20 kBq) 
containing EtOH (10 μ L) was injected directly into the tail vein of ddY mice (male, 5 weeks old). The mice were 
sacrificed at 2, 10, 30, and 60 min postinjection. The organs of interest were removed and weighed, and radioactiv-
ity was measured using a γ counter (PerkinElmer). The %ID/g of samples was calculated by comparing the sample 
counts with the count of the diluted initial dose.
In vitro autoradiography of human CAA brain sections. Six micrometer thick serial human brain sec-
tions of paraffin-embedded blocks were used for autoradiography. To completely deparaffinize the sections, they 
were incubated in xylene for 30 min two times and in 100% EtOH for 1 min two times. Subsequently, they were 
subjected to 1-min incubation in 90% EtOH and 1-min incubation in 70% EtOH, followed by a 5-min wash in 
water. Each slide was incubated with a 50% EtOH solution of [99mTc]SB2A or [99mTc]BT2B (370 kBq/mL) at room 
temperature for 1 h. For blocking experiments, the adjacent sections were incubated with a 50% EtOH solution 
of [99mTc]SB2A or [99mTc]BT2B (370 kBq/mL) in the presence of nonradioactive PIB (1.0 mM). The sections were 
washed in 50% EtOH for 3 min two times and exposed to a BAS imaging plate (Fuji Film, Tokyo, Japan) for 2 h. 
Autoradiographic images were obtained using a BAS5000 scanner system (Fuji Film). After autoradiographic 
examination, the same sections were immunostained by an antibody against Aβ (1–40) to confirm the presence 
of Aβ depositions. For immunohistochemical staining of Aβ (1–40), the sections were autoclaved for 15 min in 
0.01 M citric acid buffer (pH 6.0) to activate the antigen. After three 5-min incubations in PBS-Tween 20 (PBST), 
they were incubated with anti-Aβ (1–40) primary antibody (BA27; Wako, Osaka, Japan) at room temperature 
overnight. Subsequently, they were incubated in PBST for 5 min three times, and incubated with biotinylated goat 
anti-mouse IgG (Wako) at room temperature for 3 h. After three 5-min incubations in PBST, the sections were 
incubated with Streptavidin-Peroxidase complex at room temperature for 30 min. After three 5-min incubations 
in PBST, they were incubated with diaminobenzidine (Merck, Hesse, Germany) as a chromogen for 5 min. After 
washing with water, the sections were observed under a microscope (BIOREVO BZ-9000; Keyence Corp., Osaka, 
Japan).
Ex vivo autoradiography using Tg2576 and wild-type mice. Tg2576 transgenic mice (female, 29 
months old) and wild-type mice (female, 29 months old) were used as the AD model and age-matched control, 
respectively. A saline solution (150 μ L) of [99mTc]SB2A or [99mTc]BT2B (18.5 MBq) containing EtOH (30 μ L) was 
injected through the tail vein. The mice were sacrificed at 30 min postinjection. The brains were immediately 
removed, embedded in carboxymethylcellulose solution and then frozen in a dry ice/hexane bath. Sections of 30 μ 
m were cut and exposed to a BAS imaging plate (Fuji Film) overnight. Autoradiographic images were obtained 
using a BAS5000 scanner system (Fuji Film). After autoradiographic examination, the same sections were stained 
by thioflavin-S to confirm the presence of Aβ depositions. For thioflavin-S fluorescent staining, the sections were 
immersed in a 100 μ M thioflavin-S solution containing 50% EtOH for 3 min, washed in 50% EtOH for 1 min 
two times, and examined using a microscope (Keyence Corp.) equipped with a GFP-BP filter set. Additionally, 
the same sections were immunostained by anti-CD31 antibody to confirm the presence of endothelial cells. For 
immunohistochemical staining of CD31, the sections were incubated in PBST for 5 min three times, and incu-
bated with anti-CD31 primary antibody (SZ31; Abcam, Cambridgeshire, U.K., dilution 1:50) at room tempera-
ture overnight. After three 5-min incubations in PBST, anti-rabbit secondary antibody (Dako, California, USA) 
incubation was carried out at room temperature for 3 h. Subsequently, the sections were incubated in PBST for 
5 min three times, and incubated with diaminobenzidine (Merck) as a chromogen for 5 min. After washing with 
water, the sections were observed under a microscope (Keyence Corp.).
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